Search Results

You are looking at 1 - 3 of 3 items for

  • Author or Editor: Wolfgang C. Winkelmayer x
  • Refine by Content Type: All x
Clear All Modify Search
Wolfgang C. Winkelmayer

The recent introduction of the Centers for Medicare and Medicaid Services (CMS) End-Stage Renal Disease Prospective Payment System and the subsequent discussions about potential quality measures on how to monitor it have once again highlighted a sore point for many in the nephrology community: the evidence supporting most of our practice is weak, to say the least. Large randomized trials that have shaped most of the care in the general population have systematically excluded patients with advanced chronic kidney disease (CKD), including those requiring dialysis. Many of the trials that were specifically conducted in patients with advanced CKD or ESRD

Wolfgang C. Winkelmayer and Michel Jadoul

Over the past decade, Kidney Disease: Improving Global Outcomes (KDIGO) has established as a leading global force in making observations about the practice of kidney health care and in synthesizing recommendations for best practices. This has occurred through staging Controversies Conferences with global experts and practitioners on relevant topics in kidney health, developing Clinical Practice Guidelines, and building a portfolio of Implementation Programs through which the products from the aforementioned two activities are interpreted and discussed in the local or regional context. All these activities are based on the premise articulated in KDIGO’s mission statement: to improve the health of

Ahmed A. Awan, Wolfgang C. Winkelmayer, and Bhamidapati V. Murthy

Posttransplantation anemia (PTA) is an oft-neglected aspect of posttransplantation care that is associated with adverse outcomes for the kidney allograft and the recipient. The prevalence of anemia in kidney transplant recipients (KTRs) is very high, ranging from 25% to 40% depending on the definitions used, parameters measured, and average time since transplantation across study populations (13). The American Society of Transplantation (AST) and the World Health Organization have defined anemia as hemoglobin <13 g/dL in men or <12 g/dL in women. On the basis of these definitions, at the time of kidney